Background: Thrombocytopenia in hospitalized patients is a common cause for hematologic consultation. Our experience in the community hospital setting can inform treating physicians of the causes for and need to treat thrombocytopenia. Here we describe our clinical experience from 2 community hospitals over a 22-month period, wherein a single hematologist was consulted for 97 cases of thrombocytopenia in 93 patients.
Methods: Referred patients underwent history, physical, review of old records and imaging, relevant laboratory testing, review of the peripheral smear, and a bone marrow aspirate and biopsy if clinically indicated.
Results: Thirty-five patients had a primary hematologic cause for their thrombocytopenia. Fifty-one had secondary causes for thrombocytopenia. Eleven patients had no discernible etiology for their thrombocytopenia. The most common hematologic diagnoses were immune thrombocytopenia purpura (n = 12), heparin-induced thrombocytopenia (n = 6), in vitro platelet clumping (n = 4), quite remarkably acute progranulocytic leukemia (n = 4), and thrombotic thrombocytopenia purpura (n = 3). The latter 3 were immediately diagnosed by reviewing the peripheral smear, which led to appropriate therapy. The most common nonhematologic etiologies were liver disease (n = 21), bacterial sepsis (n = 12), and oral medication (n = 7). Although the thrombocytopenia was mostly nonacute, immediate hematologic interventions were needed for 21 patients. Four patients died, none from complications of thrombocytopenia.
Conclusions: Thrombocytopenia in hospitalized patients requires consideration of multiple etiologies and review of the peripheral smear. Liver disease is often overlooked as a cause for thrombocytopenia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjmed.2019.10.027 | DOI Listing |
J Med Case Rep
December 2024
Faculty of Medicine, Al-Quds University, Jerusalem, Palestine.
Background: Evans syndrome is a rare disorder characterized by the simultaneous or sequential combination of autoimmune hemolytic anemia and immunological thrombocytopenia, together with a positive direct antiglobulin test. This syndrome, which can be primary or secondary, is a rare initial manifestation of autoimmune diseases, notably systemic lupus erythematosus, with 1.7-2.
View Article and Find Full Text PDFHematol Oncol
January 2025
Département d'Hématologie, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo).
View Article and Find Full Text PDFClin J Gastroenterol
December 2024
Department of Diagnostic Pathology, National Hospital Organization Shizuoka Medical Center, 762-1 Nagasawa, Shimizu, Sunto District, Shizuoka, 411-0904, Japan.
Surgical resection is the only curative treatment for cholangiocarcinoma, but it is often diagnosed at advanced stages, making surgical resection infeasible. Recently, the concept of conversion surgery has expanded the indications for surgical treatment, thanks to advancements in both perioperative management and chemotherapy. However, it remains unclear which patients benefit most from this treatment strategy.
View Article and Find Full Text PDFTranspl Infect Dis
December 2024
Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
This case involves a 52-year-old male, who underwent a deceased donor orthotopic liver transplant 7 months prior, presented with a 2-week history of persistent fever, anemia, thrombocytopenia, and mild elevation of liver enzymes. Upon hospital admission, the patient was febbrile, alert and oriented, hemodynamically stable. Laboratory exams revealed worsening leukopenia, anemia, thrombocytopenia, hyponatremia, and elevated ferritin.
View Article and Find Full Text PDFAnn Hematol
December 2024
Department of Medical Oncology, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, 212 Yuhua East Road, Baoding, 071000, Hebei, China.
The first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has recently undergone major changes, and targeted therapies have ushered in a new era of CLL/SLL treatment. Scientists in different countries have successively analyzed the efficacy of various drugs, but safety studies are relatively insufficient. Therefore, this systematic evaluation and retrospective meta-analysis was conducted to compare the differences in adverse effects and their incidence among first-line treatment regimens for CLL/SLL.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!